Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia

Overview of attention for article published in BMC Health Services Research, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 7,947 followers.

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia https://t.co/7ykXIdqjQf

RT @PSynnott29: New paper from Ethiopia finds 1L treatment w/ caspofungin isn't cost-effective vs. fuconazole-initiated treatment for inpat…

RT @PSynnott29: New paper from Ethiopia finds 1L treatment w/ caspofungin isn't cost-effective vs. fuconazole-initiated treatment for inpat…

RT @PSynnott29: New paper from Ethiopia finds 1L treatment w/ caspofungin isn't cost-effective vs. fuconazole-initiated treatment for inpat…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.